FDA approves HemoCleanse lung cancer study
This article was originally published in Clinica
Executive Summary
HemoCleanse and IDT have received approval from the FDA to begin a feasibility study of HemoCleanse's BioLogic-HT system for whole-body hyperthermia treatment for metastatic non-small cell lung cancer. The treatment involves elevating body temperature to control or destroy viruses and other heat sensitive organisms and HemoCleanse believes it may increase the effectiveness of chemotherapy. The study will be conducted at the University of Texas Medical Branch at Galveston, Texas.